Median leverages proprietary AI technologies to turn medical images into powerful insights, and better diagnose, treat, monitor cancer patients. With iCRO, our imaging services for oncology trials, we provide biopharma companies with key data on patient response to candidate drugs. Imaging Lab, our advanced iCRO offering, drives cancer drug development success with transformative AI-powered insights. With iBiopsy, we deploy next generation end-to-end AI/ML tech based SaMDs, to help healthcare professionals diagnose cancers early. Our first SaMD on the market will be for lung cancer screening.